Sanson M, Hoang-Xuan K
Clinique neurologique, Hôpital de La Salpêtrière, Paris.
Rev Prat. 1996 Feb 15;46(4):464-8.
Although prognosis of malignant gliomas did not change dramatically for the last 15 years, tumorigenesis is much better understood. The study of the genetic alterations occurring in these tumors allowed to recognise the most critical genes involved, which are either overexpressed oncogene, or inactivated tumor suppressor gene. Gene therapy is a natural outcome of such progresses. One way of tumor gene therapy is based on correction of genetic defect either by introducing the missing tumor suppressor gene or by blocking overexpression of an activated oncogene. Alternatively, "destructive" gene therapy is based on a "suicide" gene introduced in tumor cells. These approach results now in phase 1 protocol.
尽管在过去15年里恶性胶质瘤的预后没有显著变化,但对肿瘤发生的了解却深入了许多。对这些肿瘤中发生的基因改变的研究使人们能够识别出最关键的相关基因,这些基因要么是过度表达的癌基因,要么是失活的肿瘤抑制基因。基因治疗是这些进展的自然结果。肿瘤基因治疗的一种方法是通过引入缺失的肿瘤抑制基因或阻断激活的癌基因的过度表达来纠正基因缺陷。或者,“破坏性”基因治疗基于在肿瘤细胞中引入“自杀”基因。这些方法目前已进入1期临床试验方案。